164 related articles for article (PubMed ID: 15305187)
21. Combined carboplatin and etoposide chemotherapy for patients with recurrent glioma.
Chen J; Zhao Y; Hou X; Gao X; Shi Q; Li S; Huang H
Ann Palliat Med; 2021 Dec; 10(12):12650-12656. PubMed ID: 35016422
[TBL] [Abstract][Full Text] [Related]
22. Carboplatin combined with carmustine and etoposide in the treatment of glioblastoma.
Boiardi A; Silvani A; Milanesi I; Botturi M; Broggi G
Ital J Neurol Sci; 1992 Dec; 13(9):717-22. PubMed ID: 1483854
[TBL] [Abstract][Full Text] [Related]
23. Phase II trial of cisplatin plus temozolomide, in recurrent and progressive malignant glioma patients.
Silvani A; Eoli M; Salmaggi A; Lamperti E; Maccagnano E; Broggi G; Boiardi A
J Neurooncol; 2004 Jan; 66(1-2):203-8. PubMed ID: 15015788
[TBL] [Abstract][Full Text] [Related]
24. A phase 1 study of vinblastine in combination with carboplatin for children with low-grade gliomas: a Children's Oncology Group phase 1 consortium study.
Jakacki RI; Bouffet E; Adamson PC; Pollack IF; Ingle AM; Voss SD; Blaney SM
Neuro Oncol; 2011 Aug; 13(8):910-5. PubMed ID: 21764821
[TBL] [Abstract][Full Text] [Related]
25. Treatment of paediatric pontine glioma with oral trophosphamide and etoposide.
Wolff JE; Westphal S; Mölenkamp G; Gnekow A; Warmuth-Metz M; Rating D; Kuehl J
Br J Cancer; 2002 Oct; 87(9):945-9. PubMed ID: 12434281
[TBL] [Abstract][Full Text] [Related]
26. Phase I and pharmacologic study of sequential topotecan-carboplatin-etoposide in patients with extensive stage small cell lung cancer.
Miller AA; Al Omari A; Murry DJ; Case D
Lung Cancer; 2006 Dec; 54(3):379-85. PubMed ID: 17049403
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of accelerated fractionation radiation therapy with carboplatin followed by PCV chemotherapy for the treatment of anaplastic gliomas.
Levin VA; Yung WK; Bruner J; Kyritsis A; Leeds N; Gleason MJ; Hess KR; Meyers CA; Ictech SA; Chang E; Maor MH
Int J Radiat Oncol Biol Phys; 2002 May; 53(1):58-66. PubMed ID: 12007942
[TBL] [Abstract][Full Text] [Related]
28. Treatment of recurrent malignant supratentorial gliomas with the association of carboplatin and etoposide: a phase II study.
Ameri A; Poisson M; Chauveinc L; Chen QM; Delattre JY
J Neurooncol; 1997 Apr; 32(2):155-60. PubMed ID: 9120545
[TBL] [Abstract][Full Text] [Related]
29. Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.
Reardon DA; Desjardins A; Vredenburgh JJ; Gururangan S; Sampson JH; Sathornsumetee S; McLendon RE; Herndon JE; Marcello JE; Norfleet J; Friedman AH; Bigner DD; Friedman HS
Br J Cancer; 2009 Dec; 101(12):1986-94. PubMed ID: 19920819
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of temozolomide and escalating doses of oral etoposide for adults with recurrent malignant glioma.
Korones DN; Benita-Weiss M; Coyle TE; Mechtler L; Bushunow P; Evans B; Reardon DA; Quinn JA; Friedman H
Cancer; 2003 Apr; 97(8):1963-8. PubMed ID: 12673724
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of temozolomide treatment in patients with high-grade glioma.
Oshiro S; Tsugu H; Komatsu F; Ohmura T; Ohta M; Sakamoto S; Fukushima T; Inoue T
Anticancer Res; 2009 Mar; 29(3):911-7. PubMed ID: 19414327
[TBL] [Abstract][Full Text] [Related]
32. Phase I study of paclitaxel, carboplatin, and increasing days of prolonged oral etoposide in ovarian, peritoneal, and tubal carcinoma: a gynecologic oncology group study.
Rose PG; Rodriguez M; Waggoner S; Greer BE; Horowitz IR; Fowler JM; McGuire WP
J Clin Oncol; 2000 Aug; 18(16):2957-62. PubMed ID: 10944128
[TBL] [Abstract][Full Text] [Related]
33. Phase II trial of irinotecan plus celecoxib in adults with recurrent malignant glioma.
Reardon DA; Quinn JA; Vredenburgh J; Rich JN; Gururangan S; Badruddoja M; Herndon JE; Dowell JM; Friedman AH; Friedman HS
Cancer; 2005 Jan; 103(2):329-38. PubMed ID: 15558802
[TBL] [Abstract][Full Text] [Related]
34. Response and progression in recurrent malignant glioma.
Hess KR; Wong ET; Jaeckle KA; Kyritsis AP; Levin VA; Prados MD; Yung WK
Neuro Oncol; 1999 Oct; 1(4):282-8. PubMed ID: 11550320
[TBL] [Abstract][Full Text] [Related]
35. A phase I trial of surgery, Gliadel wafer implantation, and immediate postoperative carboplatin in combination with radiation therapy for primary anaplastic astrocytoma or glioblastoma multiforme.
Limentani SA; Asher A; Heafner M; Kim JW; Fraser R
J Neurooncol; 2005 May; 72(3):241-4. PubMed ID: 15937647
[TBL] [Abstract][Full Text] [Related]
36. In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.
Taki T; Ohnishi T; Arita N; Hiraga S; Hayakawa T
J Neurooncol; 1998 Jan; 36(1):41-53. PubMed ID: 9525824
[TBL] [Abstract][Full Text] [Related]
37. Phase II Study of Bevacizumab and Vorinostat for Patients with Recurrent World Health Organization Grade 4 Malignant Glioma.
Ghiaseddin A; Reardon D; Massey W; Mannerino A; Lipp ES; Herndon JE; McSherry F; Desjardins A; Randazzo D; Friedman HS; Peters KB
Oncologist; 2018 Feb; 23(2):157-e21. PubMed ID: 29133513
[TBL] [Abstract][Full Text] [Related]
38. Radiotherapy combined with nimustine hydrochloride and etoposide for malignant gliomas: results of a pilot study.
Tanaka M; Shibui S; Nomura K; Nakanishi Y
Jpn J Clin Oncol; 2001 Jun; 31(6):246-50. PubMed ID: 11463801
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of topotecan and etoposide for non-Hodgkin lymphoma: correlation of topoisomerase-DNA complex formation with clinical response.
Kancherla RR; Nair JS; Ahmed T; Durrani H; Seiter K; Mannancheril A; Tse-Dinh YC
Cancer; 2001 Feb; 91(3):463-71. PubMed ID: 11169927
[TBL] [Abstract][Full Text] [Related]
40. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: an open-label, multicentre, randomised, phase 3 trial.
Baize N; Monnet I; Greillier L; Geier M; Lena H; Janicot H; Vergnenegre A; Crequit J; Lamy R; Auliac JB; Letreut J; Le Caer H; Gervais R; Dansin E; Madroszyk A; Renault PA; Le Garff G; Falchero L; Berard H; Schott R; Saulnier P; Chouaid C;
Lancet Oncol; 2020 Sep; 21(9):1224-1233. PubMed ID: 32888454
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]